LOGIN  |  REGISTER
Chimerix
Terns Pharmaceuticals

Numinus Wellness to Participate in the Healthcare Virtual Conference Presented by Maxim Group and hosted by M-Vest on June 20-22, 2023

June 08, 2023 | Last Trade: C$0.05 0.00 0.00

VANCOUVER, BC, June 8, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will present at the Healthcare Virtual Conference presented by Maxim Group LLC and hosted by M-Vest, on June 20-22, 2023.

Payton Nyquvest, Founder and CEO of Numinus, will participate in a Mental Health Care Clinics panel discussion on Wednesday, June 21, 2023 at 10:00 am ET / 7:00 am PT. In addition, Mr. Nyquvest will participate in a Numinus-focused Fireside Chat at 11:00 a.m. ET / 8:00 a.m. PT on Thursday, June 22, 2023.

This conference will be live on M-Vest. To attend, sign up to become an M-Vest member and register here.

For more information about the conference, or to schedule a one-on-one meeting with Numinus' management, please email This email address is being protected from spambots. You need JavaScript enabled to view it..

About Numinus

Numinus Wellness (TSX: NUMI; OTCQX: NUMIF) helps people to heal and be well through the development and delivery of innovative mental healthcare and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedInFacebookTwitter, and Instagram.

Forward-looking statements

Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including but not limited to the risks set forth in the Company's annual information form dated December 12, 2022 and available on SEDAR at www.sedar.com. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page